Rosuvastatin versus Atorvastatin to prevent Contrast induced Nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-CIN trial)

Acta Cardiologica

Volumn 68, Issue 5, 2013, Pages 488-494

  Kaya, Ahmet ^a   Kurt, Mustafa ^b   Tanboǧa, Ibrahim Halil ^c   Işik, Turgay ^b   Ekinci, Mehmet ^b   Aksakal, Enbiya ^c   Kaya, Yasemin ^b   Topçu, Selim ^c   Sevimli, Serdar ^c  

^a ORDU UNIVERSITY   (Turkey)

^b Erzurum Education and Research Hospital   (Turkey)

^c ATATURK UNIVERSITY   (Turkey)

Author keywords

Contrast induced nephropathy; ST segment elevation myocardial infarction; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; ENOXAPARIN; HEPARIN; IOPROMIDE; ROSUVASTATIN; CONTRAST MEDIUM; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CONTRAST INDUCED NEPHROPATHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; ANGIOCARDIOGRAPHY; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC USE; DOSE RESPONSE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FOLLOW UP; GLOMERULUS FILTRATION RATE; INCIDENCE; KIDNEY; KIDNEY DISEASES; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; RADIOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TURKEY; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEART INFARCTION; KIDNEY DISEASE; METHODOLOGY; TURKEY (REPUBLIC);

CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME; TURKEY;

EID: 84887026941     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.1080/ac.68.5.2994472     Document Type: Article

References (28)

1. Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast induced nephropathy. Int J Cardiol 2012; 158: 186-92.
2. Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, Sakuma T, Yoshida S, Sutani Y, Iwasaka T. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. nAm J Cardiol 2010; 105: 624-8.
3. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004; 44: 1393-9.
4. Uyarel H, Cam N, Ergelen M, Akkaya E, Ayhan E, Isik T, Cicek G, Gunaydin ZY, Osmonov D, Gul M, Demirci D, Guney MR, Ozturk R, Yekeler I. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction: incidence, a simple risk score, and prognosis. Arch Med Sci 2009; 5: 550-8.
5. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: A meta-analysis. Int J Cardiol 2011; 151: 348-53.
6. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75.
7. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: Which benefit for which patient? Acta Cardiol 2003; 58: 555-60.
8. Rundback JH, Nahl D, Yoo V. Contrast-induced nephropathy. J Vasc Surg 2011; 54: 575-9.
9. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl J Med 1985; 312: 932-6.
10. Harjai KJ, Raizada A, Shenoy C, Sattur S, Orshaw P, Yaeger K, Boura J, Aboufares A, Sporn D, Stapleton D. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 2008; 101: 812-9.
11. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy. Int J Cardiol 2011; 153: 323-5.
12. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, Yalcin S, Alemdar R. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010; 61: 711-4.
13. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, Montinaro A, Di Sciascio G. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty contrast-induced nephropathy] trial. Am J Cardiol 2011; 108: 1-7.
14. Wickenbrock I, Perings C, Maagh P, Quack I, van Bracht M, Prull MW, Plehn G, Trappe HJ, Meissner A. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol 2009; 98: 765-72.
15. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6: 1451-8.
16. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010; 122: 2451-5.
17. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005; 172: 1461-71.
18. Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, Hirano K, Kanaide H, Takeshita A. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 1896-901.
19. J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(23 Suppl 1): III39-III43.
20. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
21. Zhao JL, Yang YJ, Zhang YH, You SJ, Wu YJ, Gao RL. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 2008; 126: 435-6.
22. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98-103.
23. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering are they clinically relevant? Eur Heart J 2003; 24: 225-48.
24. Tawfik MK, Ghattas MH, Abo-Elmatty DM, Abdel-Aziz NA. Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction. Eur Rev Med Pharmacol Sci 2010; 14: 499-506.
25. Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, Kinderlerer A, Randi AM, Haskard DO. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002; 91: 696-703.
26. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009; 26: 958-64.
27. Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 2011; 10: 969-86.
28. Herregods MC, Daubresse JC, Michel G, Lamotte M, Vissers E, Vandenhoven G. Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. Acta Cardiol 2008; 63: 493-9.